Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
Open Access
- 1 May 1994
- Vol. 35 (5) , 707-708
- https://doi.org/10.1136/gut.35.5.707
Abstract
A 50 year old man is described with hepatic dysfunction and chronic pancreatitis in whom greatly increased concentrations of the pancreatic tumour marker CA 19-9 combined with an abnormal appearance at endoscopic retrograde cholangiopancreatography lead to the false suspicion of pancreatic carcinoma. CA 19-9 concentrations should be interpreted with caution in patients with intrinsic liver disease or biliary obstruction.Keywords
This publication has 11 references indexed in Scilit:
- Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseasesEuropean Journal of Clinical Investigation, 1992
- CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory studyClinica Chimica Acta; International Journal of Clinical Chemistry, 1992
- Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy.Radiology, 1991
- Evaluation of a Serologic Marker, CA19-9, in the Diagnosis of Pancreatic CancerAnnals of Internal Medicine, 1989
- Pancreatic function testing: serum PABA measurement is a reliable and accurate measurement of exocrine function.Gut, 1988
- CA 19-9 and CA 50 in Benign and malignant pancreatic and biliary diseasesCancer, 1988
- Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bankInternational Journal of Cancer, 1984
- Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA)Digestive Diseases and Sciences, 1983
- Hepatic Clearance of Serum GlycoproteinsClinical Science, 1983